/wp-content/uploads/2024/12/2024-Cover.jpg)
Ranbaxy
Dalal Street’s Suryanamaskar Explained
Shailendra Tyagi
Sun’s bet is that it can fix the factory glitches, get US regulatory clearances, and turn the Sun-Ranbaxy combine into a low-cost generics export powerhouse.
The Art of Letting Go
Indian business groups are learning to separate emotion from valuation. For shareholders, this can only be a good sign.
Burning Cash to Bust Those Blocks
The Indian pharma gameplan appears more like irrational overreach and less like an achievement
Magazine
Subscribe today and save up to 85% off the cover price
-
-
© 2024 Open Media Network Pvt. Ltd.